Nepafenac (Synonyms: AHR 9434; AL 6515)

Cat. No.: HY-17357 Purity: 99.51%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Nepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac.

For research use only. We do not sell to patients.

Nepafenac Chemical Structure

CAS No. : 78281-72-8

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent
10 mM * 1 mL in DMSO ready for reconstitution	USD 50	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 50	In-stock	Estimated Time of Arrival: December 31
Solid
25 mg	USD 45	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 120	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Nepafenac:

Nepafenac-d₅ In-stock

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

Biological Activity
Purity & Documentation
References
Customer Review

Description

Nepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac. IC50 value: Target: COX-2 Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery.

IC₅₀ & Target^[1]^[4]

COX-1

64.3 μM (IC₅₀)

COX-2

Clinical Trial

Molecular Weight

254.28

Formula

C₁₅H₁₄N₂O₂

CAS No.

78281-72-8

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(N)CC1=CC=CC(C(C2=CC=CC=C2)=O)=C1N

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (393.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.9327 mL	19.6634 mL	39.3267 mL
5 mM	0.7865 mL	3.9327 mL	7.8653 mL
10 mM	0.3933 mL	1.9663 mL	3.9327 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.51%

Select Batch:

Data Sheet (271 KB) SDS (0 KB)

COA (245 KB) LCMS (98 KB)

Handling Instructions (2659 KB)

References

[1]. Gamache DA, Graff G, Brady MT et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [Content Brief]

[2]. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84. [Content Brief]

[3]. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006 Feb;22(2):397-404. [Content Brief]

[4]. Marshall JC, Fernandes BF, Di Cesare S et al. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis. 2007 Sep;28(9):2053-8. [Content Brief]

[5]. Singh R, Alpern L, Jaffe GJ et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259-69. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.9327 mL	19.6634 mL	39.3267 mL	98.3168 mL
	5 mM	0.7865 mL	3.9327 mL	7.8653 mL	19.6634 mL
	10 mM	0.3933 mL	1.9663 mL	3.9327 mL	9.8317 mL
	15 mM	0.2622 mL	1.3109 mL	2.6218 mL	6.5545 mL
	20 mM	0.1966 mL	0.9832 mL	1.9663 mL	4.9158 mL
	25 mM	0.1573 mL	0.7865 mL	1.5731 mL	3.9327 mL
	30 mM	0.1311 mL	0.6554 mL	1.3109 mL	3.2772 mL
	40 mM	0.0983 mL	0.4916 mL	0.9832 mL	2.4579 mL
	50 mM	0.0787 mL	0.3933 mL	0.7865 mL	1.9663 mL
	60 mM	0.0655 mL	0.3277 mL	0.6554 mL	1.6386 mL
	80 mM	0.0492 mL	0.2458 mL	0.4916 mL	1.2290 mL
	100 mM	0.0393 mL	0.1966 mL	0.3933 mL	0.9832 mL

Nepafenac Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Nepafenac78281-72-8AHR 9434 AL 6515AHR9434AHR-9434AL6515AL 6515AL-6515COXBacterialCyclooxygenaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks